Verastem, Inc.
Case Overview
Status: | Status: Investigating |
Company Name: | Company Name: Verastem, Inc. |
Ticker: | Ticker: VSTEM |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP is investigating potential claims against Verastem, Inc. (“Verastem” or the “Company”) (NASDAQ: VSTM). The investigation concerns whether Verastem and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
On May 23, 2024, Verastem issued a press release “announc[ing] the initial interim safety and efficacy results from the ongoing RAMP 205 Phase 1/2 clinical trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in the first-line in patients with metastatic pancreatic cancer.” Among other items, Verastem disclosed that 12 patients experienced 19 treatment-emergent serious adverse events. On this news, the price of Verastem shares declined by $8.06 per share, or approximately 66.17%, from $12.18 on May 23, 2024 to close at $4.12 per share on May 24, 2024.
On May 23, 2024, Verastem issued a press release “announc[ing] the initial interim safety and efficacy results from the ongoing RAMP 205 Phase 1/2 clinical trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in the first-line in patients with metastatic pancreatic cancer.” Among other items, Verastem disclosed that 12 patients experienced 19 treatment-emergent serious adverse events. On this news, the price of Verastem shares declined by $8.06 per share, or approximately 66.17%, from $12.18 on May 23, 2024 to close at $4.12 per share on May 24, 2024.